Biopharma companies to FDA: Internationally harmonize plans to standardize safety data and analysis

As the FDA pushes to more broadly standardize the way it collects safety data to better detect concerning signals with pharmaceuticals, biopharma companies are pushing back on why there isn’t a more international approach given the global nature of the industry.

The current lack of standardization around the analysis of...

Click to view original post